Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2023-06-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押展期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of a pledge on shares held by the controlling shareholder of the company. It details the number of shares pledged, the pledge period extension, and related shareholder information. There is no financial report, earnings data, or management discussion. The document is a formal disclosure about a capital-related event (share pledge extension) rather than a report or presentation. This fits the category of Capital/Financing Update (CAP). The document length is short and focused on a specific financing event, not a report publication or regulatory filing. Therefore, the classification is CAP with high confidence.
2023-06-26 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an 'Annual Equity Distribution Implementation Announcement' for the year 2022 by Huabang Life Health Co., Ltd. It details the dividend distribution plan approved at the 2022 Annual General Meeting, including dividend amounts, record dates, payment methods, and related shareholder information. The document is relatively short (1859 characters) and primarily announces the implementation of the dividend distribution rather than providing a full annual report or detailed financial statements. It also references the approval of the plan at the AGM and provides specifics on dividend payment but does not contain comprehensive financial data or management discussion. Therefore, this document fits the category of a Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2023-06-07 Chinese
关于控股股东部分股份解除质押及质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged and released, the dates, and the pledgee information. There is no financial statement, earnings data, or management discussion. The document is a formal disclosure about share pledging activities, which fits the category of Share Issue/Capital Change announcements related to changes in share pledges. The document length is short (2813 characters) and it is not an announcement of a report publication but a direct disclosure. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change).
2023-06-02 Chinese
2022年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Huabang Life Health Co., Ltd. It details the convening, attendance, voting procedures, and results of the AGM. The document does not contain the actual annual report or financial statements but rather confirms the legality and validity of the AGM process and voting outcomes. It is not a report itself but a legal opinion related to the AGM. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the official voting results and procedures of the AGM.
2023-05-17 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2022 Annual General Meeting (AGM) of shareholders of 华邦生命健康股份有限公司. It details the voting results on various proposals including the 2022 board work report, supervisory board report, financial statements, profit distribution plan, annual report approval, and auditor appointment. The document includes attendance information, voting percentages, and legal opinion confirming the validity of the meeting and voting process. The content is focused on announcing the results of the shareholder meeting rather than presenting the full annual report or financial statements themselves. The document length is relatively short (2194 characters) and it serves as an official announcement of the AGM resolutions and voting outcomes. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-17 Chinese
东海证券股份有限公司关于华邦生命健康股份有限公司所属山东凯盛新材料股份有限公司境内上市之持续督导意见
Audit Report / Information Classification · 95% confidence The document is titled as a "持续督导意见" (Continuous Supervision Opinion) issued by an independent financial advisor (东海证券股份有限公司) regarding the domestic listing of a subsidiary company (山东凯盛新材料股份有限公司) of 华邦生命健康股份有限公司. It references regulatory requirements under the "上市公司分拆规则(试行)" (Listing Company Spin-off Rules) by the China Securities Regulatory Commission (证监会公告[2022]5号). The document contains detailed analysis of the company's business, financial data, and compliance with disclosure obligations during the supervision period. It is a formal opinion report issued by the independent financial advisor after continuous supervision, not an annual or interim report, nor a simple announcement. It is not a proxy, voting result, or management change announcement. The document length (8308 characters) and content indicate it is a substantive report. This type of document corresponds to an Audit Report / Information (AR) category, as it is a standalone audit/supervision report related to regulatory compliance and financial condition, but not a full annual report or earnings release. FY 2022
2023-05-10 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.